Organisation profile

Cellular and Molecular Medicine (CMM) is an internationally recognised centre of excellence for the study of cancer biology, infection and immunology and stem cell biology.

Academics from across the school’s various areas of expertise have been involved in studies that have significantly improved our scientific understanding of human disease and facilitated the development of best practice in the clinical environment. Of note, a multinational collaboration involving experts in surgery and tissue-engineering from the school made medical history when they carried out the first ever transplant of a bioengineered windpipe, with life-changing results. The research made TIME magazine’s Top 10 Medical Breakthroughs in 2008. In 2009 Bristol became one of the UK’s leading centres in the testing of a children’s swine flu vaccine during the H1N1 flu outbreak. The study was conducted with the Health Protection Agency, funded by the NHS National Institute for Health Research and was adopted by the Medicines for Children Research Network. Renewal in 2011 of Cancer Research UK five year programme funding means that the internationally renowned research into colorectal cancer prevention and treatment can continue a longstanding commitment to developing clinical trials involving non-steroidal anti-inflammatory drugs.
We pride ourselves on how our researchers and students contribute to a growing portfolio of research that demonstrates how the University is at the forefront of efforts to turn science into medicine.

Research within the School of Cellular and Molecular Medicine is focused on three strategic research themes:

- Infection and immunity
- Cancer biology
- Tissue engineering and stem cell therapies